Description: Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Home Page: www.sanofi.com
54, Rue La BoEtie
Paris,
75008
France
Phone:
33 1 53 77 40 00
Officers
| Name | Title |
|---|---|
| Mr. Paul Hudson | CEO & Director |
| Mr. Jean-Baptiste Chasseloup de Chatillon | Exec. VP & CFO |
| Mr. Laurent Gilhodes | Principal Accounting Officer and VP of Corp. Accounting |
| Mr. Bruno Ménard | Chief Information officer |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care |
| Eva Schaefer-Jansen | Head of Investor Relations |
| Mr. Dante Beccaria | Global Compliance Officer & VP |
| Mr. Roy Papatheodorou | Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity |
| Mr. Josep Catlla | Head of Communications |
| Mr. Pierre Chancel | Sr. VP of Global Diabetes and Sr. VP of Global Marketing |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 10.3306 |
|---|---|
| Trailing PE: | 18.1716 |
| Price-to-Book MRQ: | 1.6008 |
| Price-to-Sales TTM: | 2.7339 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 95442 |